

HERAMED LIMITED COMPLETES \$1.98 MILLION PLACEMENT

- Firm commitments of \$1.98 million (before costs) in a single tranche Placement to new and existing institutional and sophisticated investors
- \$1.98 million Placement at 1.2 cents per share, a ~4.8% discount to the 15-day VWAP of 1.26 cents
- The proceeds of the Placement will provide working capital to support the execution of near-term commercial opportunities in the U.S. as well as opportunities in Australia, and Europe.

HeraMED Limited (ASX: HMD) ('HeraMED' or the 'Company'), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce it has received firm commitments to raise to raise \$1.98 million (before costs) through a private placement of 165 million fully paid ordinary shares at an issue price of \$0.012 per share. The placement attracted strong support from both new and existing institutional and sophisticated investors, underlining continued confidence in the Company's strategic direction and commercialisation progress.

HeraMED Managing Director and CEO, Anoushka Gungadin, commented, ""We are very pleased to have secured \$1.98 million in new capital, which enables HeraMED to continue executing against our commercial roadmap in the U.S., where market interest and opportunity are accelerating.

We are grateful for the support from new and existing investors to support our long-term vision and our ability to convert the growing pipeline of health systems and partners into tangible outcomes. This raise provides critical working capital and extends our cash runway as we focus on unlocking high-impact opportunities, building scale, and delivering value to mothers, clinicians, and shareholders alike.

I'd like to thank all participating investors for their belief in our mission to make digitally enabled maternity care more accessible, efficient, and effective across the globe."

About the Placement

HeraMED has received firm commitments to raise \$1.98 million (before costs) via the issue of 165,000,000 new ordinary shares, at 1.2 cents per share in a private Placement. The issue price is a 4.8% discount to the 15-day VWAP of 1.26 cents before HeraMED went into trading halt pre-market on Thursday 31st of July 2025.

The Placement will be issued under the Company's capacity under ASX Listing Rule 7.1 (77,439,726 ordinary shares) and 7.1A (87,560,274 ordinary shares).

The proceeds of the Placement will fund working capital to support commercial deployments, pilots and integration of HeraCARE into large health systems, private clinics and a number of platforms in the US as well as Australia and Europe.

Westar Capital Limited was engaged as Lead Manager to the Placement and receives a 6% capital raising fee and will also receive 20 million options using the Company's capacity under ASX Listing Rule 7.1 on the following terms

- with an exercise price of 2 cents;
- with an expiry date of 24 December 2028;
- transferable and exercisable upon issue;
- unlisted; and
- ranked equally to other options of the company.

The indicative timetable for the Placement is as follows:

Summary of key dates	Date/Time
ASX Announcement of Placement	4 August 2025
Settlement of Placement Shares	12 August 2025
Allotment and trading of Placement Shares	13 August 2025

The above timetable is indicative only and may change without notice.

ENDS

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited
Managing Director & CEO
Anoushka Gungadin
M: +61 431 131 649
E: anoushka@hera-med.com

CFO & Company Secretary
Cameron Jones
T: +61 400 086 399
E: cameron.jones@bio101.com

Chairman
Tim Chapman
T: +61 419 897 062
E: tchapman@claritycap.com.au

About HeraMED Limited (ASX: HMD)

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.